Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1904 in Advanced or Metastatic Biliary Tract Cancer
NCT07450976Phase 2Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Mar 2026
- Primary completion
- Dec 2030
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of garetatug rezetecan in biliary tract cancer (BTC), sponsored by Suzhou Suncadia Biopharmaceutical. Started Mar 2026; status: recruiting.
02
Drugs
garetatug rezetecan
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07450976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07450976.